摘要
目的探讨齐拉西酮与奎硫平治疗首发精神分裂症的疗效及安全性。方法将63例首发精神分裂症患者随机分为两组，研究组32例，口服齐拉西酮治疗，对照组31例，口服奎硫平治疗，观察8周。于治疗前及治疗第1周、2周、4周、8周末采用阳性与阴性症状量表、副反应量表评定临床疗效及不良反应。结果两组治疗后阳性与阴性症状量表总分及各因子分均较治疗前有显著性下降（P均〈0．01），同期两组间评分均无显著性差异（P均〉0．05）。治疗8周末，研究组显效率75．0％，有效率87．5％，对照组分别为71．0％，87．1％，两组间无显著性差异（P〉0．05）。两组不良反应均轻微，研究组主要表现为失眠、锥体外系反应等，对照组主要表现为体质量增加等。结论齐拉西酮与奎硫平治疗首发精神分裂症疗效均显著，对阴性、阳性症状及一般精神病理均有效，且起效快，安全性高，依从性好。
Objective To explore the clinical efficacy and safety of ziprasidone vs. quetiapine in the treatment of first-episode schizophrenia. Methods Sixty-three first-episode schizophrenics were randomly divided into research group（n = 32）took orally ziprasidone and control group（n =31）did quetiapine for 8 weeks. Clinical efficacies were assessed with the Positive and Negative Syndrome Scale （PANSS） and adverse reactions with the Treatment Emergent Symptom Scale（TESS） before treatment and at the end of the 1st, 2nd, 4^th and 8^th week. Results Since the end of the 1st week,the total and each factor scores of the PANSS of both groups lowered more significantly compared with pretreatment（all P〈0.01）, there were no significant differences in group comparisons in the corresponding time period（all P〉0.05）. At the end of the 8th week,obvious effective and effective rates were 75.0% and 87.5% in the research and 71.0% and 87.1% in the control group, respectively, which showed no significant difference（P〉0.05）. Adverse reactions of both groups were mild, those of the research were mainly insomnia and extrapyramidal system reactions and the control group increased body weight and so on. Conclusion Both ziprasidone and quetiapine have evident effects on first-episode schizophrenia, are effective on negative, positive symptoms and general psychopathology, take elects faster, and has higher safety and better compliance.
出处
《临床心身疾病杂志》
CAS
2010年第1期15-16,共2页
Journal of Clinical Psychosomatic Diseases
